These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20169510)

  • 41. When should prophylaxis therapy in inhibitor patients be considered?
    Young G; Auerswald G; Jimenez-Yuste V; Konkle BA; Lambert T; Morfini M; Santagostino E; Blanchette V
    Haemophilia; 2011 Sep; 17(5):e849-57. PubMed ID: 21418444
    [TBL] [Abstract][Full Text] [Related]  

  • 42. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors.
    Tarantino M; Aledort L
    Transfusion; 2001 Dec; 41(12):1628-9. PubMed ID: 11778084
    [No Abstract]   [Full Text] [Related]  

  • 43. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches.
    Meeks SL; Batsuli G
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):657-662. PubMed ID: 27913543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
    Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient.
    Rosenfeld SB; Watkinson KK; Thompson BH; Macfarlane DE; Lentz SR
    Thromb Haemost; 2002 May; 87(5):925-6. PubMed ID: 12038803
    [No Abstract]   [Full Text] [Related]  

  • 46. A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.
    Santagostino E; Young G; Carcao M; Mannucci PM; Halimeh S; Austin S
    Expert Rev Hematol; 2018 Feb; 11(2):87-97. PubMed ID: 29258406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Some recent developments regarding arthropathy and inhibitors in haemophilia.
    Rodriguez-Merchan EC
    Haemophilia; 2008 Mar; 14(2):242-7. PubMed ID: 18201189
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
    Berntorp E
    Haemophilia; 2009 Jan; 15(1):3-10. PubMed ID: 19016901
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors.
    Dargaud Y; Lambert T; Trossaert M
    Haemophilia; 2008 Jul; 14 Suppl 4():20-7. PubMed ID: 18494689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overview of inhibitors.
    Astermark J
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.
    Franchini M; Manzato F; Salvagno GL; Montagnana M; Zaffanello M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):814-9. PubMed ID: 20169518
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emicizumab for the treatment of haemophilia A: a narrative review.
    Franchini M; Marano G; Pati I; Candura F; Profili S; Veropalumbo E; Masiello F; Catalano L; Piccinini V; Vaglio S; Pupella S; Liumbruno GM
    Blood Transfus; 2019 May; 17(3):223-228. PubMed ID: 31246563
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost effectiveness of prophylactic treatment with activated prothrombin complex concentrate in a patient with inhibitor-positive hemophilia A.
    Nakamura S; Morimoto A; Oh Y; Hayase T; Kashii Y; Gunji Y; Momoi MY
    Blood Coagul Fibrinolysis; 2012 Apr; 23(3):235-7. PubMed ID: 22322137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thrombelastography-guided factor VIIa therapy in a surgical patient with severe hemophilia and factor VIII inhibitor.
    Pivalizza EG; Escobar MA
    Anesth Analg; 2008 Aug; 107(2):398-401. PubMed ID: 18633014
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC; van den Berg HM
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunobiology of inhibitor development in hemophilia A.
    Fijnvandraat K; Bril WS; Voorberg J
    Semin Thromb Hemost; 2003 Feb; 29(1):61-8. PubMed ID: 12640567
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential role of thrombelastography in the monitoring of acquired factor VIII inhibitor hemophilia A: report on a 78-year-old woman with life-threatening bleedings.
    Spiezia L; Meneghetti L; Dalla Valle F; Tognin G; Radu C; Saggiorato G; Fadin M; Zanon E; Simioni P
    Clin Appl Thromb Hemost; 2009; 15(4):470-6. PubMed ID: 18930953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies.
    Teitel JM; Sholzberg M
    Blood Rev; 2013 Mar; 27(2):103-9. PubMed ID: 23452718
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibitory antibodies in hemophilia A.
    Pratt KP
    Curr Opin Hematol; 2012 Sep; 19(5):399-405. PubMed ID: 22814650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high-titer inhibitor unresponsive to factor VIII inhibitor bypassing activity.
    Watts RG
    Am J Hematol; 2005 May; 79(1):58-60. PubMed ID: 15849767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.